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AIM OF THE STUDY 
 
To evaluate the quality and duration of postoperative analgesia 
with bilateral superficial cervical plexus block for patients undergoing 
thyroidectomy surgeries under general anaesthesia using 0.25% 
Bupivacaine (Group B) and 0.25% Bupivacaine with Clonidine 5 μg/ml 
(Group C) 
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INTRODUCTION 
Pain is a protective mechanism designed to alert the body to 
potentially injurious stimuli. The International Association for the Study 
of Pain (IASP) defines pain as an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage. Alleviation 
of pain has been the focus of continuing human effort over centuries. 
Thyroid operations can cause mild to moderate incisional pain. In 
addition, discomfort in swallowing, burning sensation in the throat, 
nausea, and vomiting can be caused by the operation or by general 
anaesthesia. These affect a majority of the patients, especially within the 
first day after operation. Surgeons and anaesthesiologists have attempted 
to prevent or treat these problems with various modalities, such as opioids 
and nonsteroidal antiinflammatory drugs, or with additional locoregional 
anaesthesia techniques. Locoregional anaesthesia, such as local 
anaesthetic wound infiltration21, bilateral superficial cervical plexus block 
(BSCPB)5, and bilateral combined superficial and deep cervical plexus 
block3, can potentially reduce postoperative pain in patients who undergo 
thyroidectomy. 
Bilateral superficial cervical plexus block (BSCPB) is a popular 
regional anaesthesia technique for its feasibility and efficacy. Clonidine, 
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an alpha-2 adrenergic agonist, has been used as an adjuvant to local 
anaesthetics in various regional techniques9,12,13  to extend the duration of 
block. This study was conducted to see the efficacy of Clonidine as an 
adjunct to Bupivacaine in post operative pain relief following bilateral 
superficial cervical plexus block for thyroid surgeries. All patients 
undergoing thyroidectomy surgeries under general anaesthesia, received 
bilateral superficial cervical plexus block using 6ml of 0.25% 
Bupivacaine (Group B) or 6ml of 0.25% Bupivacaine with Clonidine 5 
μg/ml (Group C) on each side. 
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CERVICAL PLEXUS 
The anterior rami of the upper four cervical nerves unite by a series 
of loops to form the cervical plexus, whose function is the supply of the 
skin and muscles of the neck and the innervation of the diaphragm.  
The branches of the cervical plexus can be divided into four 
groups. 
1. Communicating branches, which pass to the hypoglossal nerve, 
and which also pass to the vagus and to the cervical sympathetic 
chain. 
2. Superficial branches, which supply cutaneous fibres to the neck. 
3. Deep branches, to the neck muscles. 
4. The phrenic nerve, which is the motor nerve of the diaphragm 
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THE SUPERFICIAL CERVICAL PLEXUS 
The superficial cervical plexus comprises superficial branches that 
can be tabulated into ascending, transverse and descending groups. 
1  Ascending - Lesser occipital nerve (C2); great auricular nerve 
(C2, 3) 
2  Transverse - Anterior cutaneous nerve of neck (C2, 3) 
3  Descending - Supraclavicular nerves (C3, 4)  
The lesser occipital nerve (C2) hooks around the spinal accessory 
nerve (XI), and then ascends along the posterior border of the 
sternocleidomastoid. It pierces the deep fascia in the upper part of the 
posterior triangle, and then splits up into three branches. 
1.  Auricular - to the upper third of the medial aspect of the 
external ear 
2.  Mastoid - to the skin over the mastoid process 
3.  Occipital - to the occipital area immediately above and behind 
the mastoid 
The great auricular nerve (C2, 3) is the largest cutaneous branch of 
the cervical plexus. It hooks around the mid-point of the posterior border 
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of sternocleidomastoid, and then passes across it in the direction of the 
angle of the mandible. On this muscle it breaks up into three terminal 
branches. 
1. Auricular - supplying the lower two-thirds of the medial 
aspect of the external ear and the lateral surface of the lobule. 
2. Mastoid - to the skin over the mastoid process 
3. Facial -to the skin over the masseter and the parotid gland 
The anterior cutaneous nerve of the neck (C2, 3) emerges close 
below the great auricular nerve at the posterior border of 
sternocleidomastoid, then passes horizontally forward on the muscle, 
deep (sometimes superficial) to the external jugular vein. At the anterior 
border of sternocleidomastoid, the nerve pierces the deep fascia and splits 
into branches to supply the skin of the whole front of the neck. 
The supraclavicular nerves (C3, 4) arise as a common stem that 
emerges from behind sternocleidomastoid immediately below the other 
cutaneous nerves of the plexus. This stem soon splits into three branches - 
medial, intermediate and lateral, which pierce the deep fascia above the 
clavicle, cross this bone and supply the skin over the upper sternum, the 
upper chest wall. 
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THE DEEP CERVICAL PLEXUS 
This supplies the anterior vertebral muscles - the recti capitis, 
longus capitis and longus cervicis, as well as giving contributions to 
scalenus medius. In addition, branches pass to levator scapulae (C3, 4) 
and to two muscles whose principal innervation is from the spinal 
accessory nerve: sternocleidomastoid (C2, 3) and trapezius (C3, 4). 
CLINICAL APPLICATIONS 
Blockade of the cervical plexus is easy to perform and provides 
anaesthesia for surgical procedures in the distribution of C2 to C4, 
including lymph node dissection, plastic repair, and carotid 
endarterectomy. Bilateral blocks can be used for tracheostomy and 
thyroidectomy. Cervical plexus block can be divided into superficial and 
deep techniques.  
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SUPERFICIAL CERVICAL PLEXUS BLOCK 
The patient is placed in the supine position, with the head and neck 
turned opposite the side to be blocked. The anaesthesiologist should stand 
at the patient’s side approximately shoulder high. At the midpoint on the 
posterior border of the sternocleidomastoid muscle, the superficial 
cervical plexus is packaged so infiltration at this point produces a block. 
To perform the block, a 24-gauge, 2.5cm needle is inserted 
subcutaneously posterior to the sternocleidomastoid muscle, and 2 mL of 
local anaesthetic is injected. The needle is redirected both superiorly and 
inferiorly along the posterior border of the sternocleidomastoid, and 2 mL 
of solution is injected along each of these sites. A total of 6 mL of local 
anaesthetic is thus injected. In this fashion, a field block of the superficial 
plexus is created. If patients are properly positioned for this block, the 
superficial block rarely results in problems. Complications from improper 
performance of the block include a deeper placement of needle leading to 
deep cervical plexus block, which includes temporary Horner’s 
syndrome, phrenic nerve paralysis, and hoarseness from recurrent 
laryngeal nerve paralysis. A potential for systemic toxicity is present 
because of injection of the local anaesthesia solution into the vertebral 
artery or the external or internal jugular veins24 
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THE THYROID GLAND 
Anatomy 
Although the term thyroid is derived from the Greek word meaning 
shield, the gland is most commonly described as ‘butterfly’ shaped. The 
thyroid gland lies in the neck related to the anterior and lateral parts of the 
larynx and trachea. Anteriorly, its surface is convex; posteriorly, it is 
concave. It is composed of two lobes joined by an isthmus. The isthmus 
lies across the trachea anteriorly just below the level of the cricoid 
cartilage. The lateral lobes extend along either side of the larynx as 
roughly conical projections reaching the level of the middle of the thyroid 
cartilage. Their upper extremities are known as the upper poles of the 
gland. Similarly, the lower extremities of the lateral lobes are known as 
the lower poles. The gland is brownish- red due to a rich blood supply. 
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Innervation of the Thyroid 
Principal innervation of the thyroid gland derives from the 
autonomic nervous system. Parasympathetic fibers come from the vagus 
nerves, and sympathetic fibers are distributed from the superior, middle, 
and inferior ganglia of the sympathetic trunk. These small nerves enter 
the gland along with the blood vessels. Autonomic nervous regulation of 
the glandular secretion is not clearly understood, but most of the effect is 
postulated to be on blood vessels, hence the perfusion rates of the glands. 
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PHARMACOLOGY OF BUPIVACAINE 
Bupivacaine is a local anaesthetic drug belonging to the amino 
amide group, synthesised by A.F.Ekenstam in 1957 and brought into 
clinical use in 1963. 
It is produced for clinical use in a racemic mixture containing equal 
proportions of ‘S’ and ‘R’ enantiomers. It is supplied for clinical use as 
hydrochloride salt. 
CHEMICAL STRUCTURE 
Bupivacaine hydrochloride is (±) -1-Butyl-2´,6´-pipecoloxylidide 
monohydrochloride, monohydrate. 
 
Physicochemical and pharmacokinetic Profile26 
Molecular weight   - 288 
pKa     - 8.1 
Plasma protein binding  - 95% 
Liposolubility   - 30 
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Partition coefficient (octanol/buffer) - 3460 
Volume of distribution at steady state – 73 L 
T 1/2 (min)     - 210 
Clearance (L min-1)   - 0.58 
Mechanism of action 
Bupivacaine exerts its effect by inhibition of sodium channels. 
Bupivacaine binds to the intracellular portion of sodium channels and 
blocks sodium influx into nerve cells, which prevents depolarization. It 
acts to block conduction in nerves by decreasing or preventing the large 
transient increases in permeability of cell membrane to sodium ions that 
follows depolarisation of the membrane. Bupivacaine also reduces the 
permeability of the resting nerve membrane to potassium as well as 
sodium ions. 
Pharmacokinetics  
 Bupivacaine is rapidly absorbed from the site of injection. The rate 
of rise of plasma bupivacaine concentration and the peak plasma 
concentration depends on the route of administration. There is also 
interindividual variation and peak systemic concentration may occur 5 
and 30 mins after administration. The addition of vasoconstrictor delays 
absorption and results in lower plasma concentrations of bupivacaine. 
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Pharmacokinetic studies on the plasma profiles of bupivacaine after direct 
intravenous injection suggest a three-compartment open model. The first 
compartment is represented by the rapid intravascular distribution of the 
drug. The second compartment represents the equilibration of the drug 
throughout the highly perfused organs such as the brain, myocardium, 
lungs, kidneys and liver. The third compartment represents an 
equilibration of the drug with poorly perfused tissues, such as muscle and 
fat. The elimination of drug from tissue distribution depends largely upon 
the ability of binding sites in the circulation to carry it to the liver where 
it is metabolized. 
Metabolism 
 Bupivacaine is metabolized primarily in the liver via conjugation 
with glucuronic acid. Pipecoloxylidine is the major metabolite of 
bupivacaine. Half life is 3.5 hours in adults and 8.1 hours in neonates. 
The kidney is the main excretory organ for bupivacaine and its 
metabolites. Urinary excretion is affected by renal perfusion and factors 
affecting urinary pH. Only 5 - 10% of bupivacaine is excreted unchanged 
in the urine. 
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Clinical applications 
• Infiltration anaesthesia 
• Peripheral nerve block 
• Central neuraxial block (intrathecal, epidural, caudal) 
Contraindications 
• Known hypersensitivity to bupivacaine or to any local anaesthetic 
agent of the amide type 
• Intravenous regional anaesthesia 
Preparations available 
• 0.25%, 0.5% in 10 and 20ml vials containing methyl paraben as 
preservative 
• 5mg/ml (0.5%) bupivacaine with 80mg dextrose in 4ml ampoules 
for intrathecal injection 
Adverse reactions 
Adverse reactions are associated with excess plasma levels of the 
drug which may be due to over dosage, unintentional intravascular 
injection or slow metabolic degradation. 
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Bupivacaine is more cardiotoxic. Clinically, this is manifested by 
severe ventricular arrhythmias and myocardial depression after 
inadvertent intravascular administration of large doses of bupivacaine. 
The enhanced cardiotoxicity of bupivacaine probably is due to multiple 
factors. Bupivacaine blocks cardiac sodium channels rapidly during 
systole. However, bupivacaine dissociates much more slowly during 
diastole, so a significant fraction of sodium channels remain blocked at 
the end of diastole with bupivacaine. Thus, the block by bupivacaine is 
cumulative and substantially greater than would be predicted by its local 
anesthetic potency. Bupivacaine-induced cardiotoxicity can be very 
difficult to treat, and its severity is enhanced in the presence of acidosis, 
hypercarbia, and hypoxemia. 
The central nervous system effects are characterized by excitation 
or depression. The first manifestation may be nervousness, dizziness, 
blurred vision, or tremors, followed by drowsiness, convulsions, 
unconsciousness, and cardiac arrest. 
The ratio of the dosage required for irreversible cardiovascular 
collapse (CC) and the dosage that will produce CNS toxicity 
(convulsions) (i.e., the CC/CNS ratio) is lower for bupivacaine. 
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Allergic reactions, which may be due to hypersensitivity, 
idiosyncrasy, or diminished tolerance, are characterized by cutaneous 
lesions (e.g. urticaria), edema, and other manifestations of allergy. 
The clinical implications for cardiac resuscitation after 
intravascular injection or overdose of local anesthetic are the following:  
  
.     
• No medications are uniformly effective in facilitating 
resuscitation from bupivacaine-induced cardiac arrest or 
severe ventricular tachycardia. Basic principles of 
cardiopulmonary resuscitation should be emphasized first, 
including attention to securing the airway, providing 
oxygenation and ventilation, and performing chest 
compressions if needed. 
  
.     
• If a patient experiences profound cardiovascular depression 
or circulatory arrest after the administration of bupivacaine, 
then along with initiation of basic life support and the ACLS 
protocol a rapid bolus of Intralipid 20%, 1.5 mL/kg, be 
administered without delay, followed if necessary by an 
infusion of 0.25 mL/kg/min for the next 10 minutes. 
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PHARMACOLOGY OF CLONIDINE 
Clonidine is a centrally acting selective alpha-2 adrenergic agonist. 
It has a ratio of 220:1 alpha-2 selectivity (alpha-2: alpha-1). It is an 
imidazole derivative and was formulated in 1960, initially as a 
vasoconstrictor and nasal decongestant. 
It acts primarily by reducing the sympathetic output from the 
central nervous system. 
The chemical name is 2-(2,6-dichlorophenylamino)-2-imidazoline 
hydrochloride. The following is the structural formula:  
 
Mechanism of action 
Clonidine binds with alpha-2 adrenergic receptors which are of 
three subtypes – Alpha 2A, 2B, and 2C. Alpha 2A receptors mediate 
sedation, analgesia and sympatholysis. Alpha 2B receptors mediate 
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vasoconstriction and anti-shivering effects whereas Alpha 2C mediate the 
startle response.  
Highest densities of alpha - 2 receptors are present in the pontine 
locus ceruleus, an important source of sympathetic nervous system 
innervation of the forebrain and a vital modulator of vigilance. Clonidine 
stimulates alpha-2 adrenergic inhibitory neurons in the medullary 
vasomotor center. There is a decrease in the sympathetic nervous system 
outflow from central nervous system to peripheral tissues, manifested as 
peripheral vasodilatation and decrease in systemic blood pressure, heart 
rate and cardiac output. The ability to modify the functions of potassium 
channels in the CNS decreases anaesthetic requirements. Alpha-2 
receptors on peripheral sympathetic nervous system nerve endings inhibit 
release of norepinephrine. Neuraxial placement of clonidine inhibits 
spinal substance P release and nociceptive neuron firing. 
The mechanism whereby clonidine prolongs the duration of local 
anaesthetic blockade when injected into a nerve sheath remains 
speculative. The action of clonidine is more likely via a synergistic 
mechanism of action in combination with the local anaesthetic resulting 
in the prolonged effect16. Clonidine possibly enhances or amplifies the 
sodium channel blockade action of local anaesthetics by opening up the 
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potassium channels resulting in membrane hyperpolarization, a state in 
which the cell is unresponsive to excitatory input. Clonidine may cause 
local vasoconstriction. 
Clonidine produces sedation by decreasing sympathetic nervous 
system activity and the level of arousal. The result is a calm patient who 
can be easily aroused to full consciousness. Drugs that activate GABA 
receptors produce a clouding of consciousness and can cause paradoxical 
agitation as well as tolerance and dependence. 
EFFECTS ON ORGAN SYSTEMS 
Cardiovascular system 
The decrease in systolic blood pressure produced by clonidine is 
more prominent than the decrease in diastolic blood pressure. 
Homeostatic cardiovascular reflexes are maintained, thus avoiding 
problems of orthostatic hypotension or hypotension during exercise. 
Renal blood flow and glomerular filtration rate are maintained in the 
presence of clonidine therapy. 
Respiratory system 
Clonidine has minimal depressant effects on ventilation and does 
not potentiate ventilatory depressant effects of opioids. 
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Central nervous system 
Sedation is one of the most consistent effects mediated by central 
alpha-2 receptors. Another characteristic effect is anxiolysis. It has potent 
analgesic action that cannot be reversed by naloxone, an opioid 
antagonist, indicating that clonidine and opioid mediate analgesia through 
independent receptor mechanism.  
There is a 50% decrease in MAC of inhalational anaesthetics and 
decreased anaesthetic requirements of opioids. It also prevents shivering. 
Clonidine is also effective in suppressing signs and symptoms of 
withdrawal from opioids, benzodiazepines and ethanol. 
Pharmacokinetics 
Clonidine is rapidly absorbed after oral administration and reaches 
peak plasma concentrations within 60 – 90 minutes. Elimination half life 
of clonidine is between 9 and 12 hours, with approximately 50% 
metabolized in liver and the rest excreted unchanged in urine. 
Adverse effects 
The most common side effects produced by clonidine are sedation 
and xerostomia. Although dose-dependent adverse effects such as 
hypotension and sedation and idiosyncratic adverse effects such as 
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bradycardia do occur, clonidine does not induce profound respiratory 
depression and only mildly potentiates opioid-induced respiratory 
depression. The other side effects are constipation, dizziness, fluid 
retention, sleep disturbances, impotence, parotid swelling and depression.  
Withdrawal syndrome which is characterised by a rapid rise in 
blood pressure, with marked blood pressure lability, symptoms such as 
headache, flushing, sweating, insomnia, agitations, emotional lability, 
tremor, nausea and vomiting presents 18 – 72 hours after the last dose of 
clonidine. The syndrome can be prevented by gradual withdrawal of 
clonidine treatment or by inhibiting peripheral sympathetic nervous 
activity, with alpha and beta adrenoreceptor antagonists. 
Transient hypertension and bradycardia may occur after i.v. 
injection, caused by direct stimulation of peripheral vascular alpha-2 
receptors; an alpha–1 agonist effect may also contribute. 
Disturbance of cardiac impulse generation and conduction in the 
presence of pre existing SA and AV node disease can lead to 
symptomatic bradycardia and impairment of atrio ventricular nodal 
conduction. 
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USES  
Premedication 
 Due to its sedative effect, clonidine can be used as a premedicant. 
It also decreases the requirement of anaesthetics. Alpha-2 adrenergic 
agonists reduce the dose of intravenous hypnotic needed for anaesthesia 
induction and orotracheal intubation and also reduce the MAC of co-
administered volatile anaesthetic agents by 50%. Clonidine has been 
recommended as premedicant in a dose of 1-3 µg/kg. 
Clonidine as a premedicant is particularly useful in: 
9 Hypertensive patients have swings in blood pressure during 
surgery and premedication with clonidine is useful in reducing this 
hyper-reactivity. 
9 Chronic pain and palliative care patients receiving large doses of 
opioids may require greater perioperative opioids. This can be 
markedly reduced by premedication with clonidine. 
9 Drug addicts and alcoholics with problems such as withdrawal 
symptoms. The increased sympathetic activity in cocaine users is 
well controlled by clonidine. 
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The hemodynamic effects of clonidine are both peripheral and 
central. Stimulation of sub endothelial receptors causes vasoconstriction. 
Clonidine reduces the tonic activity of the baroreflex, decreasing arterial 
pressure and causing bradycardia. In addition, clonidine depresses 
presynaptic sympathetic neurons in the lateral horn of the thoracic spinal 
cord. Consequently, intrathecal administration causes more marked 
hypotension than parenteral administration. 
 Clonidine decreases plasma catecholamine levels. Giving clonidine 
before anaesthesia decreases cardiac output, vascular resistance, cardiac 
preload, afterload and contractility. During anaesthesia, clonidine 
increases cardiac output by improving cardiac loading conditions. In 
addition alpha-2 adrenergic agonists prevent hypertension and 
tachycardia on intubation and during surgical stimulation. During 
recovery from anaesthesia, these agents prevent tachycardia and 
hypertension, decrease the incidence of shivering and reduce oxygen 
consumption.  
Postoperative Analgesia and Regional anaesthesia 
Alpha-2 adrenergic agonists inhibit transmission of nociceptive 
stimuli in the dorsal horn of the spinal cord. Moreover they increase the 
analgesic effect of opioids. They augment local anaesthetic blockade and 
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prolong their duration of action. Clonidine has been used by epidural, 
spinal, perineural, intraarticular and parenteral routes to supplement 
postoperative analgesia produced by local anaesthetics. 
Central nerve blocks 
Clonidine produces dose dependent analgesia when administered 
into the epidural or subarachnoid space. Activation of post synaptic 
receptors in substantia gelatinosa of the spinal cord is the presumed 
mechanism for analgesic effect in central neuraxial blockade. 
Intrathecal clonidine produces analgesia of shorter duration but 
without the associated risk of respiratory depression or urinary retention 
as seen with opioid. In association with local anaesthetics the maximum 
dose of intrathecal clonidine is 1µg/kg. Giving clonidine with a local 
anaesthetic improves the quality and duration of the block, minimizes the 
pain of the tourniquet and prevents shivering. Caudal clonidine combined 
with local anaesthetics in children is very useful and increases the 
duration of anaesthesia and analgesia by a factor of 2 or 3 without 
hemodynamic side effects. The dose is between 2 and 3 µg/kg. 
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Peripheral nerve blocks 
Clonidine is commonly used as an adjuvant to local anaesthetics in 
peripheral nerve blocks where it prolongs the duration of anaesthesia and 
analgesia. Adding clonidine gives very good quality of analgesia after 
surgery with duration of over 24 hours for some lower limb blocks28. 
However there is a risk of prolonged motor block, particularly in the 
elderly patient which could prevent mobilisation. The quality of 
intravenous regional anaesthesia produced by lidocaine is improved by 
adding 150µg of clonidine. It particularly improves the tolerance of the 
tourniquet. 
Contraindications  
Disorders of cardiac impulse generation and conduction like sino 
atrial disease and atrioventricular node disease. 
PREPARATIONS 
Oral form 
 Clonidine hydrochloride tablets – 100 µg, 200 µg, 300 µg 
Transdermal form 
 Delivering clonidine 100 µg, 200 µg or 300 µg daily for 1 week 
Parenteral form 
 Clonidine hydrochloride 150 µg /ml ampoule 
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ASSESSMENT OF PAIN AND SEDATION 
Pain is a complex, multidimensional symptom resulting from a 
combination of tissue damage and nociception, previous pain experience, 
personal beliefs, culture and mood. Acute pain is relatively 
straightforward to assess as, unlike chronic pain, it generally bears a 
predictable relationship to obvious tissue damage. Because the level of 
postoperative pain tends to change rapidly throughout the postoperative 
course, especially early after surgery, a policy of regular assessment of 
pain using simple measurement tools is the best way to ensure that pain 
treatment can be appropriately titrated. Pain is considered as the “fifth 
vital sign”30.  
Tools for Evaluation of Pain30 
To assess the severity of pain and the success of treatment, some 
form of quantitation of pain is necessary. Many pain scoring systems are 
available. 
a) Categorical: A four or five point scale grading the pain as none, 
mild, moderate, severe and excruciating etc. This scale lacks 
sensitivity, but it has the advantage of simplicity. 
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b) Numerical scale: This is an 11 point scale where “0” means no pain 
and “10” is the worst imaginable pain. 
c)  Visual Analogue Scale (VAS): A 10 cm scale with no pain at one 
end and worst imaginable pain at the other, is commonly used.  
d) McGill Pain Questionnaire (MPQ): MPQ measures the sensory, 
affective, evaluative and other miscellaneous aspects of pain, thus 
measuring pain multi-dimensionally. The questionnaire contains 
about 20 aspects. 1 to 10 represents sensory aspects of pain, 11 to 
15 represent affective aspect of pain, 16 represents evaluative 
aspect of pain, 17 to 20 other miscellaneous aspects of pain. Each 
subunit has 2 to 5 words under them, representing increasing 
degree of pain and numerical value. The sum of all points gives a 
rank value, which is termed the Pain Rating Index. 
e) Happy-sad face – A child or an illiterate person could use a set of 
faces to indicate the severity of his pain. This scale shows a child’s 
face in different moods, the child is asked to select the facial 
expression that best suites the pain expression. This assesses the 
affective and fear component of pain. 
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In the study, pain was assessed using Visual Analogue Scale. 
 
Preemptive Analgesia 
Preemptive analgesia is described by Igor Kissin as “an 
antinociceptive therapy that prevents establishment of altered processing 
of afferent input, which amplifies postoperative pain.” In simpler terms, a 
preemptive analgesic intervention is one that stops or alters pain 
transmission so that pain will not become amplified by the nervous 
system. Kissin’s definition embraces the fundamental principles 
necessary for understanding the concept of preemptive analgesia: (a) that 
the central nervous system is capable of changing so that pain becomes 
either improved or worsened via central processes such as desensitization 
and sensitization, and (b) that alterations in sensory and pain transmission 
can effect such changes. Pain treated early in its course is easier to control 
than established pain. Several preemptive treatments—epidural analgesia, 
NSAIDs, nerve blocks and wound infiltration — are strongly effective.  
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Using the broader definition of preemptive analgesia that covers 
incisional (intraoperative) and inflammatory (postoperative) injury, the 
combination of experimental data and positive clinical trials strongly 
suggests that preemptive analgesia is a clinically relevant phenomenon. 
Maximal clinical benefit is observed when there is complete blockade of 
noxious stimuli with extension of this block into the postoperative period. 
By preventing central sensitization, preemptive analgesia along with 
intensive multimodal analgesic interventions could theoretically reduce 
acute postoperative pain/hyperalgesia and chronic pain after surgery. 
Sedation scoring 
The degree of sedation was evaluated by using the University of 
Michigan Sedation Scale (UMSS)8 of 0 to 4  
0 =    awake and alert  
1 =   minimally sedated/sleepy, appropriate response to   
  conversion and/or sound 
2  =    moderately sedated, somnolent/sleepy, easily aroused with 
  tactile stimulation and/or simple verbal command 
3 =  deeply sedated/deep sleep, aroused only with significant  
  stimulation 
4  =  could not be aroused 
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REVIEW OF LITERATURE 
G. Andrieu  et al 1 studied the analgesic efficacy of bilateral 
superficial cervical plexus block performed under general anaesthesia in 
patients undergoing total thyroidectomy, using ropivacaine or ropivacaine  
plus clonidine 5 µg/ml. During surgery, the median sufentanil 
requirements were significantly reduced in ropivacaine plus clonidine 
group. After surgery, the number of patients requiring nefopam within 24 
h of surgery was significantly lower in these groups than in placebo 
group. At post-anaesthetic care unit admission, median pain scores were 
also significantly lower. 
Rita Pal et al 2 studied the quality and duration of postoperative 
analgesia by cervical plexus block using bupivacaine and clonidine. 
Duration of analgesia was significantly more in bupivacaine plus 
clonidine group (8.19 ± 3.2 hours) as compared to bupivacaine group 
(5.24 ±1.6 hours). Total consumption of fentanyl citrate in postoperative 
period was also significantly less in the bupivacaine plus clonidine group. 
Sophie Aunac et al 3 evaluated the analgesic efficacy of combined 
deep and superficial cervical plexus block in patients undergoing 
thyroidectomy under general anaesthesia. Bilateral combined deep and 
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superficial cervical block was given with saline (Group 1), ropivacaine 
(Group 2), or ropivacaine plus clonidine 7.5 μg/mL (Group 3). During 
surgery, the number of additional alfentanil boluses was significantly 
reduced in Groups 2 and 3 compared with Group 1. After surgery, the 
opioid and non-opioid analgesic requirements were also significantly 
reduced in Groups 2 and 3 during the first 24 h. 
Danelli G et al 4 evaluated the effects of adding 50 µg clonidine to 
150 mg ropivacaine for superficial cervical plexus block in patients 
undergoing elective carotid endarterectomy. They concluded that it 
shortened the onset time and improved the quality of surgical anaesthesia 
in patients undergoing elective carotid endarterectomy. 
Ming-Lang Shih et al 5 investigated the analgesic efficacy of 
bilateral superficial cervical plexus block in patients undergoing 
thyroidectomy and to determine whether it reduces the adverse effects of 
general anaesthesia. They concluded that bilateral superficial cervical 
plexus block reduces general anaesthetics required during thyroidectomy. 
It also significantly lowers the severity of postoperative pain during the 
first 24 h and shortens the hospital stay. 
Nathalie Dieudonne et al 6studied the analgesic efficacy of bilateral 
superficial cervical plexus blocks performed at the end of thyroid surgery 
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using 20 mL isotonic sodium chloride or 20 mL bupivacaine 0.25% with 
1:200,000 epinephrine. The Bupivacaine group had a smaller proportion 
of patients given morphine post operatively and lower initial median pain 
scores. It was concluded that bilateral superficial cervical plexus blocks 
significantly reduce pain intensity in the postoperative period after 
thyroid surgery but do not provide optimal pain relief alone. 
Walter Pinto Neto et al 7 compared the analgesic effects of 
clonidine associated with bupivacaine to those of bupivacaine in cervical 
plexus block for carotid endarterectomy. They concluded that the 
association of 150 μg of clonidine and bupivacaine in cervical plexus 
block for carotid endarterectomy did not improve significantly the 
analgesic effects evaluated by pain severity, time until the first analgesic 
supplementations and amount of supplementary analgesics. 
Zeynep Eti et al10 compared the analgesic efficacy of bilateral 
superficial cervical plexus block and local anesthetic wound infiltration 
after thyroid surgery. They concluded that bilateral superficial cervical 
plexus block or local anesthetic wound infiltration with 0.25% 
bupivacaine did not decrease analgesic requirement after thyroid surgery. 
Rowan R. Molnar et al11 compared the addition of clonidine 5 
μg/mL to lidocaine 1.5% for cervical plexus block with  the addition of 
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epinephrine 5 μg/mL for carotid endarterectomy. The block onset time 
and duration were not different between the two groups. During the 
period from completion of the block until incision there was a significant 
heart rate increase in the epinephrine group as compared with the 
clonidine group. They concluded that clonidine 5 μg/mL is a useful 
additive to lidocaine 1.5% for cervical plexus block to reduce the 
incidence of tachycardia; however, omission of epinephrine results in 
higher serum lidocaine levels. 
Susmita Chakraborty et al8 evaluated the effect of clonidine as 
adjuvant in bupivacaine-induced supraclavicular brachial plexus block. 
They concluded that addition of a small dose of clonidine to 0.5% 
bupivacaine significantly prolonged the duration of analgesia without 
producing any clinically important adverse reactions other than sedation. 
Hutschala, D et al9 demonstrated that the admixture of clonidine to 
bupivacaine plus epinephrine prolongs and enhances brachial plexus 
blockade. Lower clonidine plasma concentrations for block treatment 
strongly suggested a local effect.  
McCartney CJ et al12 showed that Clonidine improves the duration 
of analgesia and anaesthesia when used as an adjunct to intermediate-
acting local anaesthetics for peripheral nerve blocks. They observed that 
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side-effects appear to be limited at doses up to 150 µg, but found that 
evidence is lacking for the use of clonidine as an adjunct to local 
anaesthetics for continuous catheter techniques. 
Giovanni Cucchiaro et al 13 evaluated the effects of clonidine on the 
duration of sensory and motor block and analgesia time in children who 
underwent a variety of peripheral nerve blocks. The patients received 
either bupivacaine or ropivacaine local anesthetic (LA) and a 
combination of local anesthetic and clonidine (LAC). The duration of 
sensory block was significantly longer in the LAC (17.2 ± 5 h) compared 
with that in the LA group (13.2 ± 5 h). The increase in duration was 
independent from the type of peripheral nerve block, local anesthetic used 
and operation performed.  
Andrea Casati et al 14 demonstrated that, when providing combined 
sciatic-femoral nerve block for hallux valgus repair, the addition of 1 
μg/kg clonidine to 0.75% ropivacaine prolongs the duration of 
postoperative analgesia by 3 h, with only a slight and short-lived increase 
in the degree of sedation and no hemodynamic adverse effects. 
Aruna Parameswari et al 15 demonstrated that clonidine in a dose of 
1 μg/kg added to 0.25% bupivacaine for caudal analgesia, during sub-
umbilical surgeries, prolongs the duration of analgesia of bupivacaine, 
 
 
 
 
38
without any side effects. 0.25% bupivacaine group had a mean duration 
of analgesia of 288.7 ± 259.1 min and 0.25% bupivacaine with 1 μg/kg of 
clonidine added group had a mean duration of analgesia of 593.4 ± 423.3 
min. 
H. El Saied et al 16demonstrated that addition of 150 μg of 
clonidine to ropivacaine, for brachial plexus blockade, prolongs motor 
and sensory block and analgesia, without an increased incidence of side 
effects. 
Brian D Sites et al 17 studied the effects of intrathecal clonidine for 
total knee arthroplasty using a hyperbaric bupivacaine spinal anesthetic. It 
was concluded that the co-administration of intrathecal clonidine and 
morphine decreased the 24-h IV morphine consumption and improves the 
24-h VAS score when compared with intrathecal morphine alone. 
Scott S. Reuben et al 18 studied the effect of clonidine as a 
component of intravenous regional anaesthesia. They concluded that the 
addition of 1 µg/kg clonidine to lidocaine, 0.5%, for IVRA in patients 
undergoing ambulatory hand surgery improves postoperative analgesia 
without causing significant side effects during the first postoperative day. 
Jean-Marc Bernard et al 19 studied the dose-Range Effects of 
Clonidine Added to Lidocaine for Brachial Plexus Block. 45 ml of a 
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mixture containing either 400 mg lidocaine plus saline or 400 mg 
lidocaine plus 30, 90 or 300 µg clonidine was used for axillary nerve 
block. Their study showed that 30 µg clonidine was more effective than 
90 µg clonidine in producing sensory blockade. Sedation occurred with 
clonidine 30 and 300 µg. Clonidine reduced the use of supplementary 
intravenous anesthetic agents for surgery and produced dose-dependent 
prolongation of analgesia, reaching a mean 770 min (range, 190-1440 
min) for the largest dose.  
DJ Reinhart et al 20 demonstrated that compared to 1.73% 
lidocaine, combining clonidine (10 µg /mL) with lidocaine for local 
anesthetic block for foot surgery significantly increases the duration and 
quality of postoperative analgesia. 
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MATERIALS AND METHODS 
STUDY DESIGN AND EQUIPMENT 
This was a Prospective Randomized Double Blind study conducted 
in 40 adult patients undergoing thyroidectomy surgeries from August 
2009 to September 2010 under General Anaesthesia at Chengalpattu 
Medical College Hospital, Chengalpattu. 
The study was done with Ethical Committee approval and written 
informed consent obtained from all patients included in the study. 
An Anaesthesiology Consultant who did not take any part in the 
study drew the group B or group C drug in a syringe and coded them and 
was handed over to an Anaesthesiology resident who performed the 
block. Another resident was asked to conduct the anaesthesia and also 
take down the data as per the proforma attached. 
SELECTION OF CASES 
Inclusion Criteria  
• ASA grade I & II patients of either sex  
• Age 20 – 60 yrs 
• Euthyroid patients 
• Type of surgery: Thyroidectomy 
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Exclusion criteria 
• Substernal goiters 
• Thyroidectomy with lymph node dissection 
• Inability to use the pain scale 
• Coagulation disorders 
METHOD 
40 patients under ASA I and II scheduled to undergo elective 
thyroidectomy surgery were included in this study. 
Patients included in the study underwent thorough preoperative 
evaluation which included detailed history, physical examination, 
investigations (Hemoglobin, PCV, Blood Urea, Serum Creatinine, Serum 
Electrolytes, Random blood sugar, Thyroid Function Test, Urine 
albumin-sugar, ECG, Chest X Ray, X Ray Neck) and Indirect 
Laryngoscopy. 
The patients were randomly allocated into two groups – Group B 
and Group C  
All the patients were premedicated with oral ranitidine 150mg two 
hours before surgery with a sip of water. Anaesthesia machine, drug 
trolley including emergency drugs and difficult airway tray were checked.   
 
 
 
 
42
Patients were monitored with Non invasive blood pressure 
monitoring, Pulse oximeter, five lead ECG and temperature.  
Intraoperatively patients in both groups received analgesia with 
Inj.Fentanyl Citrate 2μg/kg, 5 minutes before induction. Inj. Xylocard 
1.5mg/kg was given 90s before induction. Induction of anaesthesia was 
done with Inj.Propofol 2mg/kg. Intubation with Inj.Atracurium 0.5mg/kg.  
Maintanence with titrated Propofol infusion, nitrous oxide/ oxygen 
with top up doses of Atracurium and 0.5 μg/kg of Inj.Fentanyl Citrate 
topped up every hour. 
After intubation, bilateral superficial cervical plexus block was 
performed. The patient in the supine position and the head and neck 
turned opposite the side to be blocked. The superficial cervical plexus 
was blocked at the midpoint of the posterior border of the 
sternocleidomastoid muscle. A 24-gauge, 2.5cm needle is inserted 
subcutaneously posterior to the sternocleidomastoid muscle, and 2 mL of 
local anesthetic was injected. The needle is redirected both superiorly and 
inferiorly along the posterior border of the sternocleidomastoid, and 2 mL 
of solution was injected along each of these sites. A total of 6 mL of local 
anaesthetic was thus injected 
 
 
 
 
 
43
Group B was assigned as 6ml of 0.25% Bupivacaine on each side 
 Group C was assigned as 6ml of 0.25% Bupivacaine with 
Clonidine 5μg/ml on each side 
At the end of the surgery patient extubated following adequate 
neuromuscular reversal with Neostigmine 0.05mg/kg and Glycopyrrolate 
0.01mg/kg, intensity of pain assessed by visual analogue scale (VAS) and 
sent to PACU. 
The patients were assessed intraoperatively and postoperatively till 
VAS Score was 3 as per our proforma. 
Physiological measures assessed intraoperatively were heart rate, 
SpO2 and blood pressure at 0,5,10,15,20,25,30 minutes and every 15 
minutes there after till the end of surgery. 
Postoperatively, heart rate, blood pressure, sedation score as per  
the University of Michigan Sedation Scale and pain by visual analogue 
scale (VAS) were recorded every 30 minutes for the first 6 hrs, then every 
hour till the VAS score was 3. Rescue analgesic with Inj Fentanyl citrate 
2μg/kg was given when VAS was 3 and they were taken out of my study.  
Duration of effective analgesia was defined as the time interval 
from the administration of block to the time to reach VAS score of 3. 
Patients were monitored for any hypotension, bradycardia and excessive 
sedation. 
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Method of needle placement for a superficial cervical plexus block 
 
 
 
 
45
OBSERVATIONS & RESULTS 
Statistical Analysis 
All collected data were entered into computer using MS Excel 
software and analysed using STATA software. Descriptive analysis 
presented in the form of Tables and Graphs. The level of significance was 
0.05 used for determining the significance of different variables. Student 
‘t’ test was used to determine the significance of quantitative variables 
(heart rate, systolic, diastolic and mean arterial pressure). Chi-square 
exact test was used to test the significance of qualitative data (pain and 
sedation score). 
DEMOGRAPHICS 
1. Distribution Of Mean Age By Groups 
Parameters Group B Group C p-value 
No. of cases 20 20 
0.7 
Mean 37.6 36.2 
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2. Distribution Of Mean Weight (Kg) By Groups 
Parameters Group B Group C p-value 
No. of cases 20 20 
0.17 
Mean 55 53 
 
The groups were comparable with respect to their age and weight. 
 
3. Duration Of Surgery 
Parameters Group B Group C p-value 
No. of cases 20 20 
0.51 Mean 123.15 128.25 
Standard deviation 23.2 24.1 
 
There is no statistically significant difference between the two 
groups with respect to the duration of surgery. 
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4. Distribution of mean, standard deviation and significance 
between two groups at base recording 
 
Group 
(Nos.) 
SBP 
 
DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (20) 124 6.6 81.5 5.1 95.7 5.4 84.4 3 
C (20) 124.6 6.6 82.5 4.1 96.5 4.5 85.9 6.3 
probability P=0.77 P=0.47 P=0.6 P=0.32 
 
5. Distribution of mean, standard deviation and significance 
between two groups at 0th minute recording of intra operative 
period 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (20) 128 6.6 83.7 5.8 98.4 5.7 86.7 2.7 
C (20) 127.6 9.1 85.4 5.6 99.1 6.97 89.8 10.5 
probability 0.87 0.35 0.73 0.21 
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6. Distribution of mean, standard deviation and significance 
between two groups at 15th  minute recording of intra 
operative period 
 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (20) 113.2 7.4 73.2 4.0 86.6 4.6 77.8 4.9 
C (20) 109.6 11.3 70.4 6.4 83.5 7.3 77.2 5.5 
probability 0.24 0.10 0.12 0.72 
 
7. Distribution of mean, standard deviation and significance 
between two groups at 30th  minute recording of intra 
operative period 
 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (20) 117.5 8.3 76.3 7.7 90.1 7.5 79 5.1 
C (20) 115.9 8 76.1 5.8 89.3 6.0 77.1 4.2 
probability 0.52 0.92 0.71 0.61 
 
 
 
 
49
 
8. Distribution of mean, standard deviation and significance 
between two groups at 45th minute recording of intra operative 
period 
 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (20) 118 7.1 77.3 6.5 90.8 6.2 80.2 4.9 
C (20) 116.5 8.7 75.8 5.9 89.5 6.4 79.3 6.3 
probability 0.59 0.43 0.51 0.62 
 
9. Distribution of Mean, Standard deviation and significance 
between two groups at 60th  minute recording of intra 
operative period 
 
Group(No) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (20) 120 5.2 78.6 6 92.4 5.2 79.9 5.5 
C (20) 119.4 8.9 78.4 6.5 92 6.8 79.6 5.9 
probability 0.83 0.90 0.85 0.87 
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10.  Distribution of Mean, Standard deviation and significance 
 between two groups at 90th minute recording of intra operative 
 period 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (20) 124.5 6.7 82.2 5.6 96.3 5.6 82 5.9 
C (20) 121.8 6.1 79.1 5.5 93.3 5.1 81.1 7.6 
probability 0.18 0.08 0.08 0.67 
 
11.  Distribution of Mean, Standard deviation and significance 
 between two groups at 105th   minute recording of intra 
 operative period 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (17) 123.7 6.7 81 6.3 95.3 6.1 83 3.9 
C (16) 122.4 5.8 79.7 6.3 94 5.7 81.8 7.7 
probability 0.53 0.57 0.55 0.56 
 
There is no statistically significant difference between two 
groups of patients on systolic blood pressure (SBP), diastolic blood 
pressure (DBP), mean arterial pressure (MAP) and heart rate (HR) in the 
intraoperative period. 
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Distribution of SBP over base and intra operative period 
 
 
 
Distribution of DBP over base and intra operative period 
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Distribution of MAP over base and intra operative period 
 
 
 
Distribution of HR over base and intra operative period 
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12. Distribution of Mean, Standard deviation and significance 
 between two groups at 0th hour recording of post operative 
 period 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (20) 123.6 4.1 82.7 2.5 96.4 2.5 84.5 4.2 
C (20) 123.7 6.3 80.8 5.8 95.2 5.5 84.4 4.7 
Probability 0.95 0.19 0.38 0.91 
 
13. Distribution of Mean, Standard deviation and significance 
 between two groups at 0.5th hour recording of post operative 
 period 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (20) 121 4.4 79.4 5.2 93.3 4.4 83 3.2 
C (20) 120.5 6.6 78.2 6.5 92.3 6.2 82.7 4 
probability 0.80 0.50 0.53 0.82 
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14. Distribution of Mean, Standard deviation and significance 
 between two groups at 1st hour recording of post operative 
 period 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (20) 121.7 5.2 79.7 4.8 93.8 4.5 81.7 3.9 
C (20) 120.3 6.3 78.9 4.8 92.7 4.6 81.3 3.7 
probability 0.44 0.57 0.42 0.74 
 
15. Distribution of Mean, Standard deviation and significance 
 between two groups at 1.5th hour recording of post operative 
 period 
 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (20) 123.1 4.9 80.2 4.6 94.5 4.2 81.4 3.4 
C (20) 119.7 6.6 79.3 5.7 92.7 5.3 79.8 3.5 
probability 0.08 0.58 0.26 0.15 
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16. Distribution of Mean, Standard deviation and significance 
 between two groups at 2nd hour recording of post operative 
 period 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (19) 122.7 5.0 80.4 4.9 94.6 4.6 80.8 4.3 
C (20) 119.9 5.5 78.2 5.4 92.1 4.9 79.6 3.9 
probability 0.09 0.18 0.10 0.31 
 
17. Distribution of Mean, Standard deviation and significance 
 between two groups at 2.5th hour recording of post operative 
 period 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (19) 117.6 21.3 80.3 5.2 92.6 7.6 80.7 3.8 
C (20) 120.2 5.5 77.4 5.3 91.6 5 79.1 3.7 
probability 0.59 0.097 0.60 0.18 
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18. Distribution of Mean, Standard deviation and significance 
 between two groups at 3rd hour recording of post operative 
 period 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (19) 123.8 5.2 80.7 4.7 95 4.7 81.3 3.7 
C (20) 120.9 5.5 78.3 5.2 92.5 4.7 78.9 3.8 
probability 0.094 0.14 0.10 0.060 
 
19. Distribution of Mean, Standard deviation and significance 
 between two groups at 4th hour recording of post operative 
 period 
Group 
(Nos.) 
SBP DBP MAP HR 
Mean SD Mean SD Mean SD Mean SD 
B (12) 122.9 3.6 80.5 4.7 94.6 4.4 81.2 4.2 
C (20) 119.6 5 77.4 5 91.5 4.3 79.8 4.6 
probability 0.06 0.08 0.12 0.06 
 
There is no statistically significant difference between two 
groups of patients on systolic blood pressure (SBP), diastolic blood 
pressure (DBP), mean arterial pressure (MAP) and heart rate (HR) in the 
postoperative period. 
 
In the fifth hour there were only 3 patients in group B. In the sixth 
and seventh hours, there was only one patient in group B. Beyond this 
period there are no patients in group B. 
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Distribution of SBP in Post operative period 
 
 
 
Distribution of DBP in Post operative period 
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Distribution of MAP in Post operative period 
 
 
Distribution of HR in Post operative period 
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20. Comparison of VAS in the post operative period 
VAS at 0th postoperative hour 
Group 
(No) 
VAS 
0 1 
B (20) 20 0 
C (20) 20 0 
 
 All the patients in both the groups had a VAS of 0 at 0th 
postoperative hour. 
VAS at 0.5th postoperative hour 
Group 
(No) 
VAS 
0 1 
B (20) 19 1 
C (20) 20 0 
 
 All the patients (100%) in group C had a VAS of 0 and 19 patients 
(95%) in group B had a VAS of 0. Only 1 patient (5%) in group B had a 
VAS of 1. 
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VAS at 1st postoperative hour 
Group 
(No) 
VAS 
0 1 2 
B (20) 7 12 1 
C (20) 15 5 0 
                              Chi square = 6.7, p = 0.034 
In Group C, 75% patients had a VAS of 0, 25% had a VAS of 1.  
In Group B, 35% patients had a VAS of 0, 60% patients had a VAS 
of 1 and 5% patients had a VAS of 2. This is statistically significant  
(p = 0.034) 
VAS at 1.5th postoperative hour 
Group 
(No) 
VAS 
0 1 2 
B (20) 1 18 1 
C (20) 9 11 0 
                              Chi square = 9.1, p = 0.011 
In Group C, 45% patients had a VAS of 0, 55% had a VAS of 1. 
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 In Group B, 5% patients had a VAS of 0, 90% patients had a VAS 
of 1 and 5% patients had a VAS of 2. This is statistically significant  
(p = 0.011) 
VAS at 2nd postoperative hour 
Group 
(No) 
VAS 
0 1 2 
B (19) 0 11 8 
C (20) 3 17 0 
                              Chi square = 12.26, p = 0.002 
In Group C, 15% patients had a VAS of 0, 85% had a VAS of 1.  
In Group B, 58% patients had a VAS of 1 and 42% patients had a 
VAS of 2. This is statistically significant (p = 0.002). 
VAS at 2.5th postoperative hour 
Group 
(No) 
VAS 
0 1 2 
B (19) 0 6 13 
C (20) 1 19 0 
                              Chi square = 20.7, p = 0.0001 
In Group C, 5% patients had a VAS of 0, 95% had a VAS of 1. 
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In Group B, 32% patients had a VAS of 1 and 68% patients had a 
VAS of 2. This is statistically significant (p = 0.0001) 
VAS at 3rd postoperative hour 
Group 
(No) 
VAS  
0 1 2 3 
B (19) 0 1 16 2 
C (20) 0 19 1 0 
 
In Group C, 95% patients had a VAS of 1and 5% had a VAS of 2.  
In Group B, 5% patients had a VAS of 1 and 84% patients had a 
VAS of 2 and 11% had a VAS of 3. 
 VAS at 4th postoperative hour 
Group 
(No) 
VAS 
0 1 2 3 
B (12) 0 0 6 6 
C (20) 0 13 7 0 
 
In Group C, 65% patients had a VAS of 1and 35% had a VAS of 2. 
 In Group B, 50% patients had a VAS of 2 and 50% patients had a 
VAS of 3. 
 
 
 
 
63
In the 5th postoperative hour, there are only 3 patients in group 
B, of which 1 patient had a VAS score of 2. 2 patients had a VAS score 
of 3 and they were given rescue analgesic and were out of my study. 
 In the 6th postoperative hour, there is only 1patient in group B 
who had a VAS score of 2. In the 7th postoperative hour, there is only 
one patient in group B who had a VAS score of 3. 
The VAS score distribution of the number of patients in group B 
from 5th hour is shown in the following graph. 
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The VAS score distribution of the number of patients in group C from 5th 
hour is shown in the following graph. 
 
Average VAS score distribution over different hours of post 
operative period 
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21. Comparison of sedation score in the postoperative period 
Sedation Score at 0th postoperative hour 
Group 
Sedation Score 
0 1 
B 18 2 
C 0 20 
 
In Group B, 90% patients had a sedation score of 0 and 20% had a 
sedation score of 1.  
In Group C 100% patients had a sedation score of 1. 
Sedation Score at 0.5th postoperative hour 
Group 
Sedation Score 
0 1 
B 20 0 
C 3 17 
 Chi square = 29.5, p=0.00001 
In Group B, 100% patients had a sedation score of 0.  
In Group C 85% patients had a sedation score of 1 and 15% had a 
sedation score of 0. This is statistically significant (p = 0.00001) 
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Sedation Score at 1st postoperative hour 
Group 
Sedation Score 
0 1 
B 20 0 
C 14 6 
                              Chi square = 7.1, p = 0.011 
In Group B, 100% patients had a sedation score of 0.  
In Group C 30% patients had a sedation score of 1 and 70% had a 
sedation score of 0. This is statistically significant (p = 0.011) 
Sedation Score at 2nd postoperative hour 
Group 
Sedation Score 
0 1 
B 19 0 
C 20 0 
 
In both the groups all the patients had a sedation score of 0.  
Beyond this period patients of both groups had a score of 0. 
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Sedation Score distribution over different hours of  
post operative period 
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21. Duration of analgesia 
Mean and Standard deviation of duration of analgesia and its 
significance in groups 
Group Mean (minutes) Std. Deviation P value 
B 366 60.1 
0.00001 
C 723 94.6 
 
There is highly significant difference between two groups in the 
duration of analgesia.  
Duration of analgesia 
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DISCUSSION 
 
Pain after thyroid surgery is regarded as being of moderate 
intensity. During the first 24 h after surgery, patients require opioid and 
non-opioid analgesics. Addition of a regional anaesthesia to general 
anaesthesia is an appropriate component of multimodal analgesia in this 
setting. Bilateral superficial cervical plexus block is found to reduce 
postoperative analgesic requirements after thyroid surgery.  
Thyroidectomy surgery done only under combined superficial and 
deep cervical plexus block was associated with more serious 
complications particularly accidental injury into vertebral artery, phrenic 
nerve palsy and also it caused discomfort to the patient of being awake 
during surgery. Compared with bilateral deep cervical plexus block, 
bilateral superficial cervical plexus block has the advantage of being 
devoid of serious complications.  
The present study was designed to evaluate the effectiveness of 
Clonidine as an adjuvant to Bupivacaine for superficial cervical plexus 
block. A total of 40 patients were randomized into two groups (B & C). 
Both the groups were monitored for haemodynamic parameters like heart 
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rate, systolic and diastolic blood pressure, mean arterial blood pressure, 
duration of postoperative analgesia and sedation. 
The mechanism whereby clonidine prolongs the duration of local 
anaesthetic blockade when injected into a nerve sheath remains 
speculative. Clonidine is highly lipid soluble, easily crosses the blood 
brain barrier to interact with alpha-2 adrenergic receptors at both spinal 
and supraspinal sites within the central nervous system producing its 
analgesic effect. Epidural and intrathecal clonidine does produce 
analgesia when used as the sole analgesic agent. Clonidine alone injected 
into the nerve sheath failed to produce prolonged analgesia. 
Clonidine injected into peripheral nerve sheath may act by 
translocation via nerves (axonal transport) or blood stream to the spinal 
cord as has become evident with opioid analgesics. The effect may occur 
by direct action of clonidine on nerve fibre conduction, specifically C and 
A delta fibres. However, this would require high local concentrations and 
would not explain why clonidine alone injected into the nerve sheath 
failed to produce prolonged analgesia. The action of clonidine would then 
more likely be via a synergistic mechanism of action in combination with 
the local anaesthetic resulting in the prolonged effect16. Clonidine 
possibly enhances or amplifies the sodium channel blockade action of 
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local anaesthetics by opening up the potassium channels resulting in 
membrane hyperpolarization, a state in which the cell is unresponsive to 
excitatory input8. This is probably the only mechanism that would explain 
the extended duration of both the sensory and motor blockade. What is 
certain is that clonidine has mixed alpha-1 and alpha-2 agonist effects at 
both pre and postsynaptic receptors as well as effects on a number of 
other specific receptors. Inhibition of noradrenaline release, mediated by 
an interaction with α2-adrenergic presynaptic receptors, could be an 
alternative explanation for the enhancing effect of the peripheral 
administration of clonidine34.  Many authors favour the hypothesis that 
clonidine exerts its local anaesthetic-prolonging effect directly on the 
nerve fibre, as a result of complex interaction between clonidine and 
axonal ion channels or receptors31,32,33. Peripheral antinociception induced 
by clonidine has also been related to an α2-adrenoceptor mediated local 
release of enkephalin-like substance35. Its mechanism of action and 
effects, therefore, are likely to be compound and complex. 
In our study, both the groups were comparable with respect to 
demographic details like age, weight of the patient and duration of 
surgery. 
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In the study, the postoperative analgesia was evaluated using the 
visual analog scale. Duration of effective analgesia was defined as the 
time interval from the administration of block to the time to reach VAS 
score of 3 and it was significantly higher in the clonidine group, with a p 
value of 0.00001. Mean duration of analgesia for the clonidine group was 
723± 94.6 minutes compared to the mean duration of analgesia for the 
bupivacaine alone group of 366±60.1minutes. 
The findings were consistent with the study of Rita Pal et al 2 who 
studied the quality and duration of postoperative analgesia by cervical 
plexus block using bupivacaine and clonidine. Duration of analgesia was 
significantly more in bupivacaine plus clonidine group (8.19 ± 3.2 hour) 
as compared to bupivacaine group (5.24 ±1.6 hour). It was also consistent 
with studies of Sophie Aunac et al3 and Susmita Chakraborty et al8 who 
observed the potentiation of analgesia by addition of clonidine. 
In the postoperative period, patients administered clonidine were 
found to be sedated up to one hour. Sedation which was assessed by the 
University of Michigan Sedation Scale, never exceeded a score 1 
(minimal sedation). Moreover, the addition of clonidine did not delay 
recovery from general anaesthesia. This was consistent with findings of 
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Susmita Chakraborty et al8 who studied the effect of clonidine as an 
adjuvant in bupivacaine-induced supraclavicular brachial plexus block. 
Hemodynamic parameters measured were heart rate, systolic, 
diastolic and mean arterial pressure. There is no significant difference 
between the two groups with respect to the systolic, diastolic and mean 
arterial pressure and heart rate in the intraoperative and postoperative 
period. This was consistent with findings of Susmita Chakraborty et al8. 
Though certain studies like that of Walter Pinto Neto et al 7 have 
found out that clonidine did not enhance local anesthetic effect in 
regional anaesthesia, our study substantiated its use as an adjunct to local 
anaesthetics to provide postoperative analgesia without deleterious side-
effects. 
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CONCLUSION 
 
Thyroidectomy is routinely done under general anaesthesia 
supplemented with postoperative narcotics in our institution. 
Thyroidectomy done under general anaesthesia and bilateral superficial 
cervical plexus block gives better patient comfort in the postoperative 
period. The addition of alpha-2 adrenergic agonist Clonidine as an 
adjuvant to local anaesthetic has improved and prolonged postoperative 
analgesia and mild sedation without any significant adverse effects. There 
is lesser consumption of postoperative narcotics and it also facilitates a 
smooth transition from intraoperative to postoperative period. 
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PROFORMA 
Name:                                                       Age/ Sex:                            
IP NO:                     WT: 
Diagnosis:  Surgery  :           
   Duration of Surgery: 
Preop Assessment: 
Investigations:        
Premedication: 
Induction:    
Intubation: 
Maintanence: 
Positioning: 
Bilateral Superficial Cervical plexus block – drugs as per the random 
group B/C: 
 
 
 
 
 
INTRAOPERATIVE 
Time(min) 0 5 10 15 20 25 30 45 60 75 90 105 120 135 150 165 180 
HR                  
SBP                  
DBP                  
MAP                  
SpO2                  
Atracurium                  
Fentanyl                  
 
POSTOPERATIVE 
Time 
(HR) 
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
VAS                                 
HR                                
SBP                                
DBP                                
MAP                                
Sedation 
Score 
                               
Rescue 
analgesic 
                               
 
 
 
 
 
MASTER CHART 
DATA OF PATIENTS - INTRAOP – BUPIVACAINE GROUP 
S 
No 
 
Name 
 
Age 
 
Sex 
 
Wt 
 
BHR 
 
BSB
P 
 
BD
BP 
 
BM
AP 
0 5 10 15 
HR SBP DB
P 
MA
P 
H
R 
SBP D
B
P 
MA
P 
H
R 
SBP D
B
P 
MA
P 
H
R 
SBP D
BP 
MA
P 
1 Meena  26 F 53 90 120 84 96 92 126 86 99 88 120 82 95 86 108 69 82 84 112 72 85 
2 Kala  60 F 50 82 134 86 102 86 138 92 107 84 130 84 99 79 132 82 99 82 124 76 92 
3 Elumalai  60 M 60 80 130 82 98 84 136 88 104 88 130 85 100 82 122 79 93 80 120 74 89 
4 Manjula  27 F 57 84 117 74 88 86 113 72 86 79 111 73 86 74 98 68 78 76 108 70 83 
5 Mohana 30 F 60 84 122 81 95 88 130 86 101 82 122 84 97 79 101 69 80 83 103 72 82 
6 Valarmathi  35 F 62 85 122 84 97 88 126 85 99 84 110 71 84 82 98 65 76 78 104 66 79 
7 Vinayagam  29 M 55 76 120 84 96 82 129 74 92 76 119 69 86 74 112 68 83 75 115 73 87 
8 Saroja 58 F 50 84 130 86 101 84 134 88 103 81 126 74 91 76 112 68 83 78 114 69 84 
9 Sarisa 34 F 55 86 119 75 90 86 125 79 94 82 111 68 82 76 103 68 80 77 110 69 83 
10 Kasiammal 49 F 60 85 135 84 101 86 134 84 101 74 119 71 87 72 122 94 103 75 125 75 92 
11 Jaya 20 F 56 84 121 82 95 86 124 85 98 84 119 72 88 87 117 73 88 85 121 74 90 
12 Kanniyammal 55 F 54 84 125 86 99 86 126 87 100 85 122 84 97 79 110 78 89 82 114 82 93 
13 Nagalakshmi 25 F 50 86 122 79 93 88 126 84 98 82 122 79 93 69 103 69 80 72 105 72 83 
14 Suganya  20 F 40 88 110 70 83 90 115 69 84 86 120 84 96 74 104 69 81 69 104 71 82 
15 Noorjahan 42 F 70 84 132 85 101 86 135 84 101 90 143 92 109 81 127 84 98 71 112 78 89 
16 Vennila 29 F 55 82 119 74 89 86 124 85 98 76 96 69 78 74 108 74 85 76 112 76 88 
17 Nandakumar 27 M 62 86 122 84 97 88 126 86 99 87 120 85 97 74 118 79 92 76 109 69 82 
18 Usha 28 F 50 85 119 76 90 82 126 87 100 84 122 79 93 79 106 68 81 71 105 71 82 
19 Dhanalaxmi 40 F 55 88 126 88 101 92 130 84 99 84 121 79 93 80 119 72 88 81 122 81 95 
20 Muthammal 58 F 55 84 134 86 102 88 136 89 105 81 122 76 91 84 121 72 88 85 124 74 91 
 
 
 
 
DATA OF PATIENTS - INTRAOP – BUPIVACAINE GROUP 
 
 
S 
No 
20 25 30 45 60 75 
HR SBP DB
P 
M
AP 
HR SBP DBP MA
P 
HR SBP DBP MAP HR SBP DBP MAP HR SBP DBP MAP H
R 
SB
P 
D
BP 
MAP 
1 82 114 70 85 84 109 69 82 85 122 74 90 86 126 78 94 82 120 74 89 88 117 68 84 
2 83 128 77 94 85 125 74 91 88 132 82 99 86 128 79 95 87 122 74 90 84 124 75 91 
3 79 122 75 91 78 124 73 90 82 126 78 94 75 119 72 88 80 124 74 91 91 130 79 96 
4 82 102 60 74 84 101 71 81 85 111 76 88 87 115 79 91 79 112 77 89 84 107 77 87 
5 81 110 74 86 84 114 75 88 86 113 72 86 83 112 71 85 82 108 68 81 79 113 72 86 
6 82 111 69 83 84 114 73 87 86 115 72 86 88 119 76 90 84 117 75 89 85 122 79 93 
7 77 117 75 89 79 107 77 87 82 114 79 91 85 116 70 85 79 111 73 86 76 114 75 88 
8 74 118 73 88 84 122 74 90 79 117 72 87 82 122 76 91 77 124 78 93 76 126 84 98 
9 75 112 72 85 78 114 75 88 82 119 81 94 85 116 82 93 77 122 86 98 79 126 86 99 
10 76 121 73 89 74 120 72 88 72 119 73 88 77 116 72 87 82 125 76 92 78 129 82 98 
11 86 123 75 91 84 125 74 91 86 122 75 91 87 123 84 97 88 124 75 91 86 122 74 90 
12 76 116 78 91 77 118 79 92 75 122 82 95 74 123 83 96 82 124 84 97 79 125 85 98 
13 74 110 76 87 77 112 82 92 82 114 84 94 79 116 82 93 77 122 86 98 82 134 92 106 
14 76 111 72 85 74 114 73 87 72 108 71 83 74 109 72 84 68 114 81 92 70 121 88 99 
15 74 117 79 92 73 103 69 80 74 93 52 66 84 97 62 74 72 117 74 88 81 109 61 77 
16 78 114 78 90 82 115 82 93 85 116 78 91 84 118 82 94 87 122 84 97 85 126 86 99 
17 77 114 72 86 74 113 68 83 76 114 72 86 82 116 76 89 74 118 74 89 77 122 76 91 
18 76 111 72 85 75 114 73 87 77 121 77 92 74 119 75 90 72 122 81 95 73 125 84 98 
19 82 124 83 97 83 122 84 97 85 125 86 99 87 121 84 96 86 126 89 101 85 122 84 97 
20 87 126 81 96 86 126 85 99 79 127 89 102 84 129 91 104 82 124 89 101 86 126 88 101 
 
 
 
 
 
 
DATA OF PATIENTS - INTRAOP – BUPIVACAINE GROUP 
 
S 
No 
90 105 120 135 150 165 
HR SBP DBP MA
P 
H
R 
SB
P 
DBP MAP H
R 
SBP DB
P 
MA
P 
H
R 
SBP DBP MA
P 
HR SBP DB
P 
MA
P 
HR SB
P 
DBP MAP 
1 92 115 70 85 86 118 76 90 84 122 74 90 85 124 76 92 88 126 78 94         
2 82 127 84 98                                         
3 84 122 74 90 82 121 71 88 86 126 78 94                         
4 85 106 76 86 86 116 70 85 88 115 87 96                         
5 84 120 82 95 84 117 83 94 86 130 86 101                         
6 82 124 82 96 86 121 79 93 86 126 85 99                         
7 74 116 74 88 79 121 78 92 82 122 81 95 76 119 79 92 84 124 85 98         
8 74 130 82 98 84 128 83 98 85 129 84 99 82 127 84 98 86 132 86 101         
9 88 128 85 99                                         
10 79 130 84 99 76 128 83 98 86 126 85 99 79 127 84 98 79 128 85 99 86 129 86 100 
11 87 123 75 91 85 127 77 94 86 129 84 99 85 127 86 100                 
12 77 121 86 98 82 122 84 97 84 126 85 99                         
13 85 135 88 104 86 134 86 102 85 129 84 99 87 128 82 97                 
14 69 130 84 99 74 110 72 85 80 117 75 89                         
15 88 132 85 101 85 137 92 107 78 117 88 98 77 110 88 95 70 116 79 91 71 118 75 89 
16 84 130 92 105 82 128 87 101 86 128 86 100                         
17 78 124 82 96 80 125 85 98 84 126 86 99                         
18 75 126 85 99 86 124 81 95 86 125 84 98                         
19 85 126 86 99                                         
20 87 125 88 100 88 127 89 102 89 131 92 105 87 133 91 105 86 129 90 103         
 
 
 
 
 
DATA OF PATIENTS - INTRAOP – BUPIVACAINE + CLONIDINE GROUP 
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Name 
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e
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Wt 
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BD
BP 
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AP 
0 5 10 15 
HR SBP DB
P 
MA
P 
HR SBP DBP MA
P 
H
R 
SBP DBP MA
P 
HR SBP DBP MAP 
1 Sasikala 28 F 50 86 120 82 95 88 126 88 101 87 122 84 97 82 112 71 85 78 110 69 83 
2 Rani 42 F 55 82 130 85 100 84 136 90 105 80 128 74 92 79 119 69 86 82 124 72 89 
3 Dhanabakyam 45 F 55 88 128 85 99 90 136 84 101 82 129 82 98 79 119 71 87 74 104 68 80 
4 Anjalachi  40 F 50 84 127 84 98 90 130 86 101 84 122 79 93 86 124 74 91 85 122 69 87 
5 Saroja 59 F 52 88 134 85 101 90 140 92 108 88 130 84 99 86 129 85 100 78 128 84 99 
6 Jayanthi 20 F 54 78 118 72 87 82 122 84 97 69 109 71 84 68 98 69 79 72 97 70 79 
7 Nirmala 27 F 54 88 127 84 98 86 130 86 101 84 121 79 93 79 118 69 85 69 122 72 89 
8 Maheswari 45 F 60 80 125 84 98 88 131 92 105 74 120 72 88 76 104 69 81 78 102 68 79 
9 Ammu 20 F 50 86 117 74 88 90 120 81 86 119 110 72 85 84 98 69 79 79 94 68 77 
10 Manimegala 41 F 55 84 132 84 100 88 140 91 107 84 130 84 99 80 128 79 95 79 121 72 88 
11 Kuppammal 31 F 55 82 126 85 99 88 130 88 102 84 120 72 88 79 119 69 86 72 104 72 83 
12 Jasintha 40 F 50 86 129 88 102 110 121 88 99 100 130 91 104 94 126 85 99 83 119 84 96 
13 Muniyammal 46 F 53 88 120 80 93 86 110 80 90 80 112 85 94 79 104 76 85 73 95 66 76 
14 Parimala 24 F 55 84 125 85 98 90 140 90 107 78 117 73 88 74 101 68 79 77 117 71 86 
15 Laila 42 F 64 86 128 84 99 86 130 85 100 70 122 92 102 72 122 87 99 71 97 60 72 
16 Adhilaxmi 35 F 50 84 114 76 89 101 116 74 88 95 95 54 68 73 105 70 82 81 115 70 85 
17 Indrani 40 F 40 82 135 86 102 70 132 92 105 72 110 97 101 82 93 55 68 76 107 72 84 
18 Vanitha 24 F 55 110 110 84 93 120 111 73 86 95 87 50 62 83 108 70 83 90 102 58 73 
19 Malliga 55 F 54 86 120 80 93 80 120 79 93 70 90 52 65 72 91 60 70 68 94 65 75 
20 Loganayaki 20 F 50 86 126 84 98 88 130 85 100 84 120 84 96 82 119 79 92 79 118 78 91 
 
 
 
 
 
 
 
DATA OF PATIENTS - INTRAOP – BUPIVACAINE + CLONIDINE GROUP 
 
S 
No 
 20 25 30 45 60 75 
HR SBP DBP MAP HR SBP DBP MA
P 
HR SBP DB
P 
MA
P 
HR SBP DBP MAP HR SBP DBP MA
P 
HR SBP DBP MA
P 
1 76 114 74 87 75 102 71 81 74 114 74 87 76 112 76 88 78 118 75 89 80 120 74 89 
2 76 124 75 91 71 126 74 91 74 129 76 94 80 130 82 98 82 129 81 97 86 128 82 97 
3 75 110 72 85 72 112 74 87 76 115 78 90 80 120 81 94 84 122 82 95 86 118 79 92 
4 84 118 69 85 82 117 68 84 79 120 71 87 84 122 76 91 82 124 75 91 86 129 78 95 
5 74 129 86 100 84 130 82 98 82 132 84 100 82 129 85 100 84 133 86 102 82 128 85 99 
6 71 108 71 83 74 110 72 85 76 106 71 83 78 108 72 84 82 110 74 86 84 118 76 90 
7 74 112 69 83 72 114 68 83 76 112 71 85 84 126 76 93 82 124 75 91 86 128 78 95 
8 82 110 74 86 86 112 75 87 78 114 76 89 82 124 82 96 79 126 81 96 83 124 81 95 
9 78 103 69 80 76 108 71 83 74 108 72 84 72 110 74 86 74 112 75 87 71 119 82 94 
10 84 124 74 91 76 122 73 89 78 121 75 90 84 119 69 86 82 124 73 90 88 124 76 92 
11 69 114 74 87 74 118 75 89 75 122 78 93 84 126 84 98 86 122 81 95 82 121 82 95 
12 80 116 75 89 78 114 81 92 74 120 80 93 78 121 74 90 76 121 80 94 70 106 72 83 
13 66 100 70 80 66 110 77 88 67 105 72 83 66 98 69 79 64 94 64 74 68 107 73 84 
14 68 101 65 77 74 107 65 79 76 113 77 89 88 105 66 79 90 133 94 107 88 112 69 83 
15 74 109 69 82 75 14 72 53 73 113 73 86 72 110 72 85 76 114 75 88 81 118 74 89 
16 85 112 64 80 88 118 84 95 82 121 78 92 84 113 71 85 86 120 71 87 88 112 76 88 
17 82 110 73 85 78 124 92 103 77 125 95 105 76 123 86 98 82 113 85 94 85 127 90 102 
18 75 101 71 81 77 102 66 78 76 102 69 80 77 111 76 88 76 115 79 91 76 112 77 89 
19 66 102 70 81 68 103 72 82 66 117 79 92 64 113 75 88 71 120 85 97 74 43 79 67 
20 78 121 76 91 72 117 74 88 69 108 72 84 74 110 69 83 75 114 76 89 76 116 78 91 
 
 
 
 
 
DATA OF PATIENTS - INTRAOP – BUPIVACAINE + CLONIDINE GROUP 
 
S 
No 
90 105 120 135 150 165 
HR SBP DBP MAP HR SBP DBP MA
P 
HR SBP DB
P 
MA
P 
HR SBP DBP MAP HR SBP DBP MAP HR SBP DB
P 
MAP 
1 88 122 76 91                                         
2 88 127 81 96 88 126 79 95 90 128 86 100 88 126 85 99 90 128 86 100         
3 78 120 81 94 88 124 82 96 88 128 86 100                         
4 85 130 82 98 84 126 79 95 82 124 74 91 88 122 75 91 90 128 81 97         
5 85 130 84 99                                         
6 78 112 74 87 86 114 78 90 88 124 84 97                         
7 79 130 81 97 84 124 79 94 86 130 82 98                         
8 72 121 76 91 74 122 78 93 80 128 86 100                         
9 69 122 83 96 74 118 82 94 78 122 84 97 88 126 88 101                 
10 92 129 78 95 86 132 84 100 84 128 82 97 82 133 88 103 88 126 79 95 86 131 84 100 
11 83 122 84 97 84 126 85 99 90 126 85 99                         
12 74 118 75 89 76 126 69 88                                 
13 73 112 74 87                                         
14 97 119 78 92 100 124 85 98 82 127 84 98 78 121 85 97 78 130 84 99         
15 84 122 76 91                                         
16 87 118 68 85 73 114 69 84 75 121 73 89 91 123 79 94 90 121 80 94         
17 76 132 95 107 74 131 93 106 82 139 86 104 84 129 71 90 85 120 66 84         
18 82 117 80 92 87 114 71 85 68 111 71 84 77 119 80 93 70 115 87 96         
19 69 117 76 90 72 115 78 90 74 122 87 99 78 119 73 88                 
20 82 115 79 91 79 122 84 97 84 122 86 98                         
 
 
 
 
 
DATA OF PATIENTS - POSTOP – BUPIVACAINE GROUP 
 
S 
No 
0 HOUR 0.5 HOUR 1 HOURS 1.5 HOURS 
HR SBP DBP MA
P 
VA
S 
SS HR SBP DBP MAP VA
S 
SS HR SBP DB
P 
MA
P 
VA
S 
SS HR SBP DB
P 
MAP VAS SS 
1 88 126 78 94 0 0 86 120 76 91 1 0 84 122 75 91 2 0 85 126 74 91 3 0 
2 86 130 82 98 0 1 84 129 79 96 0 0 79 133 84 100 1 0 78 126 82 97 1 0 
3 90 130 84 99 0 0 82 126 82 97 0 0 80 124 81 95 0 0 82 130 84 99 1 0 
4 75 120 84 96 0 0 77 113 72 86 0 0 76 114 76 89 0 0 82 116 75 89 1 0 
5 88 128 84 99 0 0 84 122 81 95 0 0 82 120 79 93 1 0 85 122 81 95 1 0 
6 84 122 82 95 0 0 82 117 78 91 0 0 86 121 81 94 0 0 84 122 84 97 0 0 
7 76 120 82 95 0 0 74 119 79 92 0 0 72 119 81 94 0 0 75 122 81 95 1 0 
8 86 120 84 96 0 0 84 122 85 97 0 0 78 119 84 96 0 0 76 126 86 99 1 0 
9 86 120 84 96 0 0 85 117 79 92 0 0 79 116 78 91 0 0 78 112 74 87 1 0 
10 84 126 85 99 0 0 82 122 87 99 0 0 85 123 82 96 1 0 86 124 82 96 1 0 
11 86 125 84 98 0 0 84 122 85 97 0 0 82 126 84 98 1 0 84 127 88 101 1 0 
12 82 122 84 97 0 0 80 126 85 99 0 0 78 127 89 102 1 0 79 126 84 98 1 0 
13 86 122 85 97 0 0 85 117 79 92 0 0 84 116 78 91 1 0 79 119 82 94 1 0 
14 80 115 75 88 0 1 82 118 69 85 0 0 84 120 71 87 1 0 86 120 74 89 1 0 
15 92 130 80 97 0 0 88 122 76 91 0 0 86 124 76 92 1 0 84 124 74 91 1 0 
16 86 121 85 97 0 0 84 119 84 96 0 0 82 116 77 90 1 0 79 118 78 91 1 0 
17 80 120 82 95 0 0 82 119 79 92 0 0 84 117 75 89 0 0 79 119 77 91 1 0 
18 87 124 82 96 0 0 86 119 69 86 0 0 85 119 72 88 1 0 82 122 75 91 1 0 
19 84 122 84 97 0 0 82 119 79 92 0 0 80 126 85 99 1 0 80 127 84 98 1 0 
20 84 128 84 99 0 0 86 131 85 100 0 0 88 132 86 101 1 0 85 133 84 100 1 0 
 
 
 
 
 
DATA OF PATIENTS - POSTOP – BUPIVACAINE GROUP 
 
S 
No 
2 HOURS 2.5 HOURS 3 HOURS 3.5 HOURS 
HR SBP DB
P 
MA
P 
VA
S 
SS HR SBP DBP MAP VAS SS HR SBP DBP MAP VAS SS HR SB
P 
D
BP 
MA
P 
VAS SS 
1                         
2 82 128 85 99 2 0 84 127 84 98 2 0 85 128 86 100 2 0 86 126 85 99 3 0 
3 78 132 82 99 1 0 80 128 84 99 2 0 82 128 86 100 2 0 84 126 84 98 2 0 
4 87 115 74 88 2 0 77 118 76 90 2 0 82 120 76 91 2 0 85 119 74 89 3 0 
5 79 124 83 97 2 0 78 121 84 96 2 0 80 123 83 96 3 0       
6 85 123 86 98 1 0 84 125 84 98 1 0 85 121 81 94 1 0 84 122 83 96 2 0 
7 73 123 82 96 1 0 72 122 83 96 1 0 74 121 82 95 2 0 75 124 81 95 2 0 
8 75 130 88 102 1 0 77 32 86 68 1 0 74 129 85 100 2 0 77 127 84 98 2 0 
9 82 114 72 86 1 0 80 110 73 85 1 0 81 111 74 86 2 0 82 112 75 87 2 0 
10 87 119 80 93 1 0 86 126 82 97 2 0 85 130 84 99 2 0 84 129 83 98 3 0 
11 85 122 81 95 1 0 84 119 76 90 2 0 82 123 79 94 2 0 83 124 81 95 2 0 
12 77 124 85 98 1 0 81 122 86 98 2 0 82 127 85 99 2 0 82 126 84 98 2 0 
13 81 117 81 93 2 0 82 116 71 86 2 0 83 115 72 86 2 0 84 116 74 88 2 0 
14 84 120 75 90 1 0 85 122 76 91 2 0 82 123 74 90 2 0 83 124 73 90 2 0 
15 82 120 72 88 2 0 84 122 76 91 2 0 86 126 78 94 3 0       
16 77 120 82 95 2 0 76 122 82 95 2 0 78 123 84 97 2 0 82 125 85 98 3 0 
17 77 121 78 92 1 0 78 123 81 95 1 0 76 122 80 94 2 0 75 124 79 94 2 0 
18 77 123 74 90 1 0 79 121 71 88 1 0 82 122 74 90 2 0 75 123 75 91 2 0 
19 81 125 84 98 2 0 82 126 83 97 2 0 79 127 84 98 2 0 82 122 82 95 2 0 
20 87 131 85 100 2 0 85 132 87 102 2 0 86 133 86 102 2 0 87 131 87 102 3 0 
 
 
 
 
 
DATA OF PATIENTS - POSTOP – BUPIVACAINE GROUP 
 
S 
No 
4 HOURS 4.5 HOURS 5 HOURS 5.5 HOURS 
HR SBP DBP MAP VA
S 
SS HR SB
P 
DBP M
AP 
VA
S 
SS HR SBP DBP MAP VAS SS HR SBP DB
P 
M
AP 
VAS SS 
1                         
2                         
3 84 122 84 97 3 0                   
4                         
5                         
6 82 122 84 97 2 0 83 125 84 98 2 0 85 126 85 99 3 0       
7 76 124 83 97 3 0                   
8 76 128 86 100 2 0 77 127 87 100 3 0             
9 83 116 76 89 2 0 84 115 75 88 2 0 84 118 74 89 3 0       
10                         
11 85 126 82 97 3 0                   
12 83 125 82 96 3 0                   
13 85 118 75 89 2 0 86 119 77 91 3 0             
14 87 120 71 87 2 0 86 122 72 89 2 0 85 124 73 90 2 0 84 125 74 91 2 0 
15                         
16                         
17 74 126 84 98 3 0                   
18 77 122 76 91 2 0 82 124 75 91 3 0             
19 82 126 84 98 3 0                   
20                         
 
 
 
 
 
DATA OF PATIENTS - POSTOP – BUPIVACAINE GROUP 
 
S No 
6 HOURS 7 HOURS  
Duration of analgesia 
(Minutes) HR SBP DBP MAP VAS SS HR SBP DBP MAP VAS SS 
1             240 
2             300 
3             360 
4             330 
5             300 
6             420 
7             390 
8             420 
9             390 
10             375 
11             375 
12               360 
13               405 
14 86 124 72 89 2 0 86 126 74 91 3 0 540 
15               345 
16               330 
17               360 
18               390 
19               330 
20               360 
 
 
 
 
 
 
DATA OF PATIENTS - POSTOP – BUPIVACAINE + CLONIDINE GROUP 
 
S 
No 
0 HOUR 0.5 HOUR 1 HOURS 1.5 HOURS 
HR SBP DBP MAP 
VA
S SS HR SBP DBP MAP 
VA
S SS HR SBP DBP 
MA
P 
VA
S SS HR 
SB
P 
DB
P 
MA
P VAS SS 
1 86 126 76 93 0 1 80 124 74 91 0 1 84 120 72 88 0 1 82 112 72 85 1 1 
2 90 130 86 101 0 1 88 124 84 97 0 1 82 122 80 94 1 1 84 122 82 95 1 1 
3 90 130 84 99 0 1 86 126 80 95 0 1 88 124 80 95 0 1 84 120 82 95 0 0 
4 86 130 80 97 0 1 88 126 76 93 0 1 84 122 74 90 0 1 82 120 75 90 0 0 
5 88 133 85 101 0 1 86 130 84 99 0 1 84 132 85 101 0 0 85 133 84 100 0 0 
6 86 120 85 97 0 1 84 117 79 92 0 1 79 118 81 93 0 0 78 117 79 92 1 0 
7 86 128 84 99 0 1 84 122 79 93 0 1 82 120 74 89 0 0 79 120 72 88 1 0 
8 88 124 82 96 0 1 86 122 79 93 0 1 82 121 78 92 0 0 78 120 74 89 0 0 
9 80 124 82 96 0 1 76 120 81 94 0 1 74 119 79 92 0 0 72 118 82 94 0 0 
10 78 126 84 98 0 1 76 122 79 93 0 1 82 119 72 88 1 0 84 118 74 89 1 0 
11 88 128 86 100 0 1 84 126 85 99 0 1 86 122 84 97 0 0 74 123 81 95 0 0 
12 80 124 82 96 0 1 84 120 82 95 0 0 82 124 84 97 0 0 83 126 86 99 1 0 
13 74 110 70 83 0 1 80 112 74 87 0 1 76 114 74 87 1 0 79 113 75 88 1 0 
14 79 120 67 85 0 1 76 122 74 90 0 0 79 120 72 88 0 0 81 124 73 90 0 0 
15 86 126 82 97 0 1 84 119 78 92 0 1 82 122 81 95 0 0 76 123 83 96 1 0 
16 90 124 82 96 0 1 86 123 84 97 0 1 82 125 86 99 0 0 79 124 83 97 0 0 
17 84 111 75 87 0 1 82 107 64 78 0 0 76 105 76 86 1 0 78 107 74 85 1 0 
18 80 113 72 86 0 1 84 103 61 75 0 1 86 107 77 87 0 0 82 106 76 86 0 0 
19 80 124 88 100 0 1 76 120 86 97 0 1 78 120 84 96 1 1 80 119 93 102 1 0 
20 88 122 84 97 0 1 84 125 80 95 0 1 78 130 84 99 0 1 76 129 85 100 1 0 
 
 
 
 
 
DATA OF PATIENTS - POSTOP – BUPIVACAINE + CLONIDINE GROUP 
 
S 
No 
2 HOURS 2.5 HOURS 3 HOURS 3.5 HOURS 
HR SBP DB
P 
MAP VA
S 
SS HR SBP DB
P 
MA
P 
VA
S 
SS HR SBP DB
P 
MAP VA
S 
SS HR SBP DBP MAP VAS SS 
1 84 120 74 89 1 0 82 122 72 89 1 0 80 124 74 91 1 0 79 125 72 90 1 0 
2 80 124 84 97 1 0 78 120 81 94 1 0 80 122 81 95 1 0 82 124 82 96 2 0 
3 82 119 79 92 0 0 80 118 81 93 1 0 84 118 82 94 1 0 82 116 81 93 1 0 
4 79 120 74 89 1 0 81 118 72 87 1 0 82 124 74 91 1 0 78 126 75 92 1 0 
5 82 134 86 102 1 0 80 135 86 102 1 0 82 138 89 105 1 0 84 135 88 104 1 0 
6 72 116 78 91 1 0 74 115 74 88 1 0 76 114 72 86 1 0 78 110 70 83 1 0 
7 78 118 70 86 1 0 78 118 72 87 1 0 80 120 74 89 1 0 82 117 71 86 1 0 
8 76 118 74 89 1 0 76 117 72 87 1 0 75 118 73 88 1 0 74 121 72 88 1 0 
9 73 117 81 93 0 0 75 122 83 96 0 0 74 120 84 96 1 0 78 125 84 98 1 0 
10 81 117 72 87 1 0 79 116 76 89 1 0 81 114 72 86 1 0 82 121 73 89 1 0 
11 76 122 84 97 1 0 78 126 86 99 1 0 75 124 82 96 1 0 74 122 81 95 1 0 
12 86 122 85 97 1 0 85 126 84 98 1 0 84 119 82 94 2 0 83 117 79 92 2 0 
13 82 112 73 86 1 0 84 110 71 84 1 0 82 112 73 86 1 0 84 118 77 91 1 0 
14 82 126 77 93 1 0 76 124 75 91 1 0 74 122 74 90 1 0 75 126 76 93 1 0 
15 78 116 75 89 1 0 82 119 76 90 1 0 78 122 81 95 1 0 77 123 83 96 2 0 
16 78 121 84 96 1 0 84 119 81 94 1 0 86 123 84 97 1 0 88 125 86 99 1 0 
17 80 111 69 83 1 0 76 116 74 88 1 0 74 117 81 93 1 0 78 121 73 89 2 0 
18 86 114 79 91 0 0 84 116 70 85 1 0 80 120 72 88 1 0 84 118 74 89 1 0 
19 82 122 82 95 1 0 78 120 80 93 1 0 76 120 82 95 1 0 76 122 84 97 1 0 
20 74 128 84 99 1 0 72 127 82 97 1 0 76 126 80 95 1 0 78 122 81 95 1 0 
 
 
 
 
 
DATA OF PATIENTS - POSTOP – BUPIVACAINE + CLONIDINE GROUP 
 
S No 
4 HOURS 4.5 HOURS 5 HOURS 5.5 HOURS 
HR SBP DBP MAP VAS SS HR SBP 
DB
P 
MA
P 
VA
S SS 
H
R SBP 
DB
P 
MA
P 
V
AS SS HR SBP DBP MAP VAS SS 
1 78 119 69 86 1 0 78 120 71 87 1 0 78 117 71 86 1 0 80 116 69 85 2 0 
2 82 118 79 92 2 0 84 116 74 88 2 0 82 120 75 90 2 0 80 122 76 91 2 0 
3 85 118 78 91 1 0 83 120 82 95 2 0 84 122 84 97 2 0 86 122 85 97 2 0 
4 82 124 74 91 1 0 84 122 72 89 1 0 82 129 84 99 1 0 82 130 85 100 2 0 
5 85 132 84 100 1 0 83 129 79 96 1 0 83 128 81 97 1 0 81 130 83 99 1 0 
6 76 112 71 85 1 0 78 114 72 86 1 0 72 112 69 83 1 0 74 114 74 87 2 0 
7 82 114 70 85 1 0 84 112 73 86 1 0 82 112 74 87 2 0 79 111 71 84 2 0 
8 72 124 74 91 2 0 74 123 73 90 2 0 75 119 71 87 2 0 76 118 69 85 2 0 
9 80 122 82 95 1 0 76 117 79 92 1 0 72 118 80 93 1 0 74 122 79 93 2 0 
10 86 122 74 90 1 0 85 121 75 90 1 0 84 119 72 88 2 0 82 112 69 83 2 0 
11 72 120 82 95 1 0 73 119 79 92 1 0 76 118 78 91 2 0 75 117 81 93 2 0 
12 86 116 81 93 2 0 88 115 79 91 2 0 87 116 78 91 2 0 88 114 74 87 2 0 
13 80 115 76 89 2 0 80 114 75 88 2 0 82 112 73 86 2 0 84 113 72 86 2 0 
14 72 123 75 91 1 0 76 124 77 93 2 0 77 124 73 90 2 0 79 121 76 91 2 0 
15 75 119 79 92 2 0 84 117 78 91 2 0 83 118 79 92 2 0 82 116 75 89 2 0 
16 84 124 87 99 2 0 82 123 86 98 2 0 83 122 84 97 2 0 85 123 85 98 2 0 
17 76 110 76 87 2 0 72 108 70 83 2 0 74 108 75 86 2 0 76 107 79 88 2 0 
18 82 117 73 88 1 0 84 119 75 90 1 0 84 122 74 90 1 0 85 120 76 91 1 0 
19 78 124 85 98 1 0 80 120 84 96 1 0 82 117 82 94 1 0 84 119 81 94 2 0 
20 82 120 79 93 1 0 84 118 76 90 1 0 78 117 75 89 1 0 76 119 72 88 2 0 
 
 
 
 
 
DATA OF PATIENTS - POSTOP – BUPIVACAINE + CLONIDINE GROUP 
 
S 
No 
6 HOURS 7 HOURS 8 HOURS 9 HOURS 
HR SBP DBP MAP VA
S 
SS HR SBP DBP MAP VAS SS HR SBP DBP MAP VA
S 
SS H
R 
SBP DBP MAP VAS SS 
1 82 115 71 86 2 0 80 118 73 88 2 0 78 117 72 87 2 0 76 118 73 88 2 0 
2 78 124 74 91 2 0 78 122 73 89 2 0 80 125 75 92 2 0 82 126 80 95 3 0 
3 88 124 86 99 2 0 84 122 84 97 2 0 86 124 82 96 2 0 85 126 83 97 2 0 
4 84 129 86 100 2 0 86 128 84 99 2 0 85 129 84 99 2 0 84 128 85 99 2 0 
5 80 130 82 98 2 0 82 133 84 100 2 0 83 132 82 99 2 0 84 133 83 100 2 0 
6 76 112 72 85 2 0 75 111 71 84 2 0 72 110 73 85 2 0 76 114 74 87 3 0 
7 78 113 72 86 2 0 76 114 74 87 2 0 76 115 76 89 2 0 78 118 75 89 2 0 
8 78 117 68 84 2 0 74 119 69 86 2 0 72 120 71 87 2 0 71 119 72 88 2 0 
9 72 121 74 90 2 0 75 122 75 91 2 0 74 128 78 95 2 0 72 122 74 90 2 0 
10 79 110 72 85 2 0 78 114 73 87 2 0 83 115 72 86 2 0 84 116 79 91 3 0 
11 82 116 79 91 2 0 80 119 78 92 2 0 78 121 76 91 2 0 82 122 75 91 2 0 
12 88 118 72 87 2 0 87 119 74 89 3 0                         
13 86 116 75 89 2 0 88 117 74 88 3 0                         
14 76 122 78 93 2 0 78 124 77 93 2 0 82 126 82 97 3 0             
15 81 118 76 90 2 0 83 122 81 95 2 0 85 124 79 94 2 0 84 122 81 95 2 0 
16 86 121 84 96 2 0 88 119 79 92 2 0 84 118 75 89 2 0 82 121 77 92 3 0 
17 76 115 84 94 2 0 78 114 70 85 2 0 80 121 70 87 2 0 80 122 65 84 2 0 
18 82 120 74 89 2 0 84 122 78 93 2 0 86 120 76 91 2 0 85 122 75 91 2 0 
19 84 119 79 92 2 0 82 121 81 94 2 0 80 122 82 95 2 0 82 124 84 97 3 0 
20 78 114 74 87 2 0 74 113 72 86 2 0 76 112 71 85 2 0 74 117 74 88 2 0 
 
 
 
 
 
 
DATA OF PATIENTS - POSTOP – BUPIVACAINE + CLONIDINE GROUP 
 
S No 
10 HOURS 11 HOURS 12 HOURS  
Duration of analgesia 
(Minutes) HR SBP DBP MAP VAS SS HR SBP DBP MAP VAS SS HR SBP DBP MAP VAS SS 
1 78 120 74 89 2 0 80 120 75 90 3 0       750 
2                   690 
3 84 124 82 96 3 0             720 
4 82 128 84 99 2 0 84 130 82 98 3 0       810 
5 85 132 82 99 2 0 86 134 84 101 3 0       750 
6                   660 
7 76 119 74 89 2 0 78 120 75 90 3 0       780 
8 70 124 74 91 3 0             720 
9 73 124 73 90 2 0 76 121 78 92 3 0       795 
10                   705 
11 84 126 76 93 3 0             720 
12                   525 
13                   510 
14                   630 
15 86 123 82 96 2 0 87 124 79 94 2 0 85 124 84 97 3 0 810 
16                   690 
17 82 111 64 80 2 0 82 108 65 79 2 0 86 110 68 82 3 0 870 
18 86 124 72 89 2 0 88 126 78 94 3 0       810 
19                   675 
20 75 118 75 89 2 0 76 122 74 90 2 0 76 125 75 92 3 0 840 
 
